Pharmaceuticals in Brazil Current Demand Behavior Analysis¶
Demand Behavior¶
Demand in the Brazilian pharmaceutical market is driven by a combination of individual consumers, various businesses within the healthcare sector, and the significant role of the public health system. The market is experiencing growth, indicated by increasing market size and sales volumes in recent years.
Detailed report on the number of individual and business consumers.¶
Individual Consumers/Patients (B2C): These are the primary end-users of pharmaceutical products in Brazil. While a precise count of individual consumers is not available, the volume of retail sales provides a strong indicator of this segment's size and activity. In 2024, the retail pharmaceutical market in Brazil commercialized a significant 8.1 billion units of medication and other related products. This high volume reflects the large number of individual transactions occurring daily across the country. The demand from this segment is influenced by factors such as an aging population and increasing access to healthcare. Furthermore, a strong preference among Brazilians (90%) for increased domestic production of medicines and inputs highlights consumer sentiment related to availability and potentially affordability.
Business Consumers (B2B): Within the pharmaceutical value chain, several types of businesses act as consumers of pharmaceutical products before they reach the final individual or government end-user. These include:
- Retail Pharmacies: Comprising large chains, associative networks, and independent pharmacies, these entities are major B2B customers of pharmaceutical manufacturers and distributors. They purchase finished pharmaceutical products in bulk for resale to individual consumers. In 2024, there were approximately 93,700 pharmacies and drugstores in operation across Brazil. Large pharmacy chains like RD Saúde, Grupo DPSP, and Grupo Pague Menos represent a significant concentration of purchasing power within this segment, collectively holding around 40% of the main consumer market share among chains. These pharmacies are crucial points of access for the majority of the population.
- Hospitals and Clinics: These healthcare institutions purchase a wide range of pharmaceutical products, including specialized and high-cost medicines, for use in patient treatment within their facilities. They procure these products from manufacturers or specialized hospital distributors. The number of hospitals in Brazil was reported as 7,191 in 2023, with 62% being private. This indicates a substantial number of business consumers in the hospital and clinic sector.
- Wholesale Distributors: While also a step in the value chain, wholesale distributors are customers of pharmaceutical manufacturers, purchasing large volumes of products for subsequent distribution to pharmacies and hospitals. In 2024, distributors handled a significant portion of the retail market's volume and value, accounting for 57% of the volume (4.6 billion units) and 55.7% of the value (R$ 88.3 billion PPP). Members of Abradilan, representing major distributors, were responsible for R$ 60.8 billion in value and 2 billion units in volume moved through the distribution channel in 2024.
Government (B2G): The Brazilian Public Health System (SUS) acts as a substantial final customer, procuring large volumes of medicines through tenders and direct purchases from manufacturers and distributors to provide free or subsidized access to the population. While the ultimate recipient is the individual, the government is the direct customer in these significant B2G transactions. This segment plays a vital role in ensuring access to essential and strategic medicines.
Table showing the growth/decline in the number of customers.¶
Based on the provided information, direct quantitative data on the number of individual consumers or a precise year-over-year change in their count is not available. However, the growth in retail sales volume serves as a strong proxy for increasing individual consumer demand. Similarly, the number of business customers (pharmacies, hospitals, distributors) is presented with specific figures for recent years, allowing for an assessment of growth or stability in these segments.
| Customer Segment | Metric | 2023 | 2024 | Growth/Decline (2023-2024) | Notes |
|---|---|---|---|---|---|
| Individual Consumers | Retail Sales Volume (Units) | 7.6 billion | 8.1 billion | Growth (+6.1%) | Proxy for the number of individual transactions/consumption. |
| Retail Pharmacies | Number of Establishments | Not explicitly stated for 2023, but indicated as growing. | 93,700 | Growth (implied) | 22 new pharmacies opened daily in 2024. |
| Distributors | Retail Volume Handled (Units) | Not explicitly stated for 2023. | 4.6 billion | Growth (implied by retail volume growth) | Represents 57% of retail volume in 2024. |
| Hospitals | Number of Hospitals | 7,191 | Not explicitly stated for 2024, but 2023 figure provided. | Stable/Growth (likely) | 2023 figure is the most recent available. |
Evaluation of Growth or Decline:
The available data strongly indicates overall growth in the demand for pharmaceutical products in Brazil from 2023 to 2024. The most direct evidence comes from the retail market, which serves individual consumers. The retail sales volume increased by 6.1% from 7.6 billion units in 2023 to 8.1 billion units in 2024. This suggests a growing number of transactions and likely an increase in the overall number of individual consumers or their per capita consumption. The total pharmaceutical market also saw significant growth, increasing by 12.7% in 2024 compared to 2023, reaching approximately R$ 220.9 billion.
The number of retail pharmacy establishments is also growing, with an average of 22 new pharmacies opening daily in 2024. This expansion of the retail footprint suggests an increasing number of points of sale serving individual consumers and, consequently, a growing number of B2B customers for manufacturers and distributors. The high concentration of the market among the top pharmacy chains (approximately 40% of main consumer share) indicates significant business volume handled by these key B2B customers.
While specific year-over-year figures for the total number of hospitals and distributors are not uniformly available across 2023 and 2024 in the provided text, their significant roles and the overall market growth imply at least stability and likely growth in these business customer segments as well. The substantial volume and value of retail sales handled by distributors in 2024 further support the notion of a high level of activity within the distribution segment.
The B2G segment, represented by the SUS, remains a constant and significant source of demand, driven by the constitutional right to health and the need to supply essential medicines to the population. While the volume of government procurement can fluctuate based on budgetary and programmatic factors, the fundamental demand from the SUS is a stable feature of the market.
In conclusion, the current demand behavior in the Brazilian pharmaceutical market is characterized by a growing number of individual consumers (as indicated by rising retail sales volume) and an expanding number of business customers, particularly in the retail pharmacy sector. The significant and ongoing activity of distributors and healthcare institutions, along with the consistent demand from the public health system, contribute to an overall environment of market growth.
References¶
- Abradilan. Dez maiores farmacêuticas do Brasil detêm 48,6% das vendas.
- Abradilan. Crescimento das grandes redes de farmácias.
- Abradilan. Setor farmacêutico cresce 12,7% em 2024, mas reajuste autorizado gera dúvidas e impacto no bolso do consumidor.
- Agência Gov. Nova Indústria Brasil contribuirá para fortalecer produção de medicamentos.
- Anvisa. Anvisa divulga dados do anuário sobre a indústria farmacêutica no Brasil.
- BNDES. Cadeia farmacêutica no Brasil: avaliação preliminar e perspectivas.
- CNN Brasil. Brasil importa 90% da matéria-prima para a produção de medicamentos.
- Dr. Fisiologia. Indústria farmacêutica brasileira e suas tendências (2025).
- Febrafar. Varejo farmacêutico: veja destaques de 2024 e expectativas para 2025.
- FIA. Indústria farmacêutica: características, setores e mercado de trabalho.
- ICTQ. Os modelos de negócios farmacêuticos.
- InvesteSP. Setor farmacêutico é o que mais investe em pesquisa e desenvolvimento.
- MOOC Fiocruz. Indústria Farmacêutica no Brasil: um breve panorama.
- Medicina SA. 90% dos brasileiros preferem a produção de medicamentos e insumos no país.
- Medicina SA. Três grandes grupos de redes de farmácias concentram 40% do mercado no Brasil.
- Medicina SA. Varejo farmacêutico cresce 11% e movimenta R$ 158,4 bilhões em 2024.
- Natcofarma. Varejo farmacêutico: Confira as principais tendências.
- Omni Hospitalar. Como funciona o processo de distribuição de medicamentos?.
- VEJA. 90% dos brasileiros dizem que produção nacional de remédios deve aumentar.
- VEJA. Varejo farmacêutico cresce 11% e movimenta R$ 158,4 bi em 2024.